Results 151 to 160 of about 2,514 (185)

Temporal clonal relatedness between myeloid neoplasm and nodal T-follicular helper cell lymphoma: a retrospective study. [PDF]

Blood Neoplasia
Yan M, Stuver R, Lin KS, Johnson WT, Horwitz SM, Dogan A, Xiao W.   +6 more
europepmc   +1 more source

Methotrexate-associated Angioimmunoblastic T-cell Lymphoma Presenting with Acute Kidney Injury. [PDF]

Intern Med
Ichikawa S, Kumagai H, Onodera K, Okitsu Y, Kobayashi M, Abe S, Fujishima F, Ichinohasama R, Kameoka J, Ishii T.   +9 more
europepmc   +1 more source

Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.

Blood
Sorial MN, Malpica Castillo LE, Chiattone C, Julia E, Bachy E, Barta SK, Stuver R, Jacobsen E, Federico M, Jain H, Prince HM, Foss F, Zinzani PL, Okatani T, Kim WS, Verburgh E, Al-Mansour M, Cabrera ME, Bhagat G, Shen C, Jain S.   +20 more
europepmc   +1 more source

MUM-1 expression differentiates AITL with HRS-like cells from cHL.

, 2015
Wenyong Huang, Jianlan Xie, Xiaoqing Xu, Xue Gao, Ping Xie, Xiaoge Zhou   +5 more
openalex  

Some of the next articles are maybe not open access.

Related searches:

G17V Rhoa Mutation in Circulating DNA Is a Useful Marker for Diagnosis of AITL and AITL-Related Lymphoma

Blood, 2015
Abstract [Background] Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma. We and others reported that the G17V RHOA mutation is frequent and highly specific to AITL and AITL-like peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS).
Rie Nakamoto-Matsubara, Mamiko Sakata-Yanagimoto, Takayoshi Itô   +2 more
exaly   +2 more sources

Expression of CXCL13 by Neoplastic Cells in Angioimmunoblastic T-Cell Lymphoma (AITL)

American Journal of Surgical Pathology, 2006
Angioimmunoblastic T-cell lymphoma (AITL) represents a distinct entity among peripheral T-cell lymphomas (PTCLs). The cellular origin of AITL remains unknown, although a possible derivation from follicular helper T cells (TFH) has been suggested based on the CD4/Bcl-6 phenotype.
Jehan Dupuis, Christiane Copie-Bergman, Anne Plonquet   +2 more
exaly   +3 more sources

Characterization of CXCL13+ Neoplastic T Cells in Cutaneous Lesions of Angioimmunoblastic T-cell Lymphoma (AITL)

American Journal of Surgical Pathology, 2007
Skin manifestations of angioimmunoblastic T-cell lymphoma (AITL) are frequent, sometimes as first manifestations of the disease. In the absence of a specific marker for neoplastic cells, diagnosis of AITL in skin biopsies is often difficult. CD10 and CXCL13 have been recently recognized as characteristic markers of AITL, but have not been yet ...
Nicolas Ortonne, Jehan Dupuis, Anne Plonquet   +2 more
exaly   +3 more sources

Establishment of An Angioimmunoblastic T-Cell Lymphoma (AITL) Model in the NOG Mouse

Blood, 2011
Abstract Abstract 5207 The aim of the present study was to establish a murine AITL model. We inoculated cells from affected LN of an AITL patient intraperitoneally into NOG mice. Hepatosplenomegaly developed in these animals about 2 months later, and normal splenic architecture was replaced by multi-focal deposit of ...
Fumiko Mori, Ayako Masaki, Itô Asahi
exaly   +2 more sources

Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T‐cell lymphoma (AITL)

Pathology International, 2010
Angioimmunoblastic T‐cell lymphoma (AITL) is a peripheral T‐cell lymphoma characterized by systemic disease with polymorphous infiltrate including macrophages. Although many studies of tumor‐associated macrophage (TAM) populations in various malignant tumors have been published, only a few have dealt with activation of macrophage phenotypes such as M1 ...
Ryosuke Aoki, Yoshizo Kimura, Masanori Takeuchi   +2 more
exaly   +3 more sources

Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL

Leukemia, 2022
Fit patients with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) in relapsed or refractory (R/R) disease status often receive salvage chemotherapy followed by autologous hematopoietic stem cell transplantation (autoHCT) or allogeneic HCT (alloHCT).
Kazuaki Kameda, Shinichi Kako, Sung-Won Kim, Yoshiaki Usui, Koji Kato, Takahiro Fukuda, Naoyuki Uchida, Hikaru Kobayashi, Toshio Wakayama, Emiko Sakaida, Shingo Yano, Kazunori Imada, Miho Nara, Takashi Ikeda, Shin-ichi Fuchida, Jun Ishikawa, Hiroyuki Sugahara, Junya Kanda, Takafumi Kimura, Tatsuo Ichinohe, Yoshiko Atsuta, Eisei Kondo   +21 more
openaire   +2 more sources